Open Access
ARTICLE
HUAFANG HUANG1,2,#, GUILIN WANG3,#, DONGYUN ZENG4,5, LUZ ANGELA TORRES-DE LA ROCHE2, RUI ZHUO1,2, RUDY LEON DE WILDE2, WANWAN WANG6, ULF D. KAHLERT7,*, WENJIE SHI7,*
1 Department of Breast Surgery, EUSOMA Certificate Breast Cancer Center (No.1037/00), Guilin TCM Hospital of China, Guilin, 541002, China
2 University Hospital for Gynecology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, 26121, Germany
3 Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541002, China
4 Clinicopathological Diagnosis & Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China
5 Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes, Baise, 533000, China
6 Department of Breast and Thyroid Surgery, Xuzhou No.1 People’s Hospital, Xuzhou, 221000, China
7 Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital Magdeburg, Otto-von Guericke University, Magdeburg, 39120, Germany
* Corresponding Author: ULF D. KAHLERT. Email: ; WENJIE SHI. Email:
# These two authors contributed equally to this work
(This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Oncology Research https://doi.org/10.32604/or.2024.054642
Received 03 June 2024; Accepted 26 September 2024; Published online 15 October 2024
View
Download
Like
Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
Yudie Yang, Xia Zhang, Yajie Gao,...MicroRNA-152 Inhibits Cell Proliferation, Migration, and Invasion in Breast Cancer
Adilijiang Maimaitiming, Ailijiang...